Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 2, 2005, Pages 151-154

  Quan Jr , Walter D Y ^a   Khan, Nawazish ^b   Ramirez, Maria ^b   Taylor, W Chris ^b   Quan, Francine ^a   Vinogradov, Mikhail ^b   Walker, Paul ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Interleukin 2; Kidney cancer; Lymphokine activated killer (LAK) cells; Melanoma; Pulmonary edema

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOLYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; ENDOTHELIUM CELL; ENDOTRACHEAL INTUBATION; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY CANCER; LUNG EDEMA; LUNG METASTASIS; LUNG NODULE; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MELANOMA; PHYSICAL EXAMINATION; PLEURA FLUID; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUMOR CELL;

ADULT; AGED; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PULMONARY EDEMA;

EID: 18844451795     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.151     Document Type: Article

References (16)

1. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233.
2. Dutcher JP, Gaynor ER, Boldt DH, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991;9:641.
3. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histologic types. Cancer Res 1986;46:4973.
4. Hawkins MJ. Interleukin-2 antitumor and effector cell responses. Semin Oncol 1993;20(suppl 9):52.
5. Damle NK, Doyle LV, Bender JR, et al. IL-2-activated human lymphocytes exhibit adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 1987;138:1779.
6. Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996;2:992.
7. Zhang J, Wenthold RJ, Jr, Yu ZX, et al. Characterization of the pulmonary lesions induced in rats by human recombinant interleukin-2. Toxicol Pathol 1995;23:653.
8. Sondel PM, Hank JA, Kohler PC, et al. Destruction of autologous human lymphocytes by interleukin-2-activated cytotoxic cells. J Immunol 1986;137:502.
9. Pankonin G, Reipert B, Ager A. Interactions between interleukin-2- activated lymphocytes and vascular endothelium: Binding to and migration across specialized and nonspecialized endothelia. Immunology 1992;77:51.
10. Kitayama J, Juji T, Atomi Y, et al. Transendothelial migration activity of lympokin-3-activated killer (LAK) cells. J Immunol 1993;151:1663.
11. Kotasek D, Vercellotti GM, Ochoa AC, et al. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res 1988;48:5528.
12. Brandau S, Suttman H, Flad H, et al. Killing of fas ligand-resistant renal carcinoma cells by interleukin-2 and bcg-activated effector cells. Cancer Immunol Immunother 2000;49:369.
13. Esser MT, Dinglasan RD, Krishnamurthy B, et al. IL-2 induces fas ligand/fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T-lymphocyte clones. J Immunol 1997;158:5612.
14. Haeryfar SMM, Nagy E, Baral E, et al. Antiestrogens affect both pathways of killer cell-mediated oncolysis. Anticancer Res 2000;20:1849.
15. Berke G. The CTL's kiss of death. Cell 1995;81:9.
16. Ribeiro UJ, Basse PH, Rosenstein M, et al. Retention of adoptively transferred interleukin-2-activated natural killer cells in tumor tissue. Anticancer Res 1997;17:1115.